TME Pharma NV (XPAR:ALTME) Total Operating Expense: €2.86 Mil (TTM As of Dec. 2025)


What is TME Pharma NV Total Operating Expense?

TME Pharma NV XPAR:ALTME -3.45% Total Operating Expense is €2.86 Mil as of Dec. 2025. The stock has 4 warning signs investors should review.

TME Pharma NV's Total Operating Expense for the six months ended in Dec. 2025 was €0.90 Mil. TME Pharma NV's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €2.86 Mil.

TME Pharma NV Total Operating Expense Related Terms

TME Pharma NV Total Operating Expense Historical Data

* Premium members only.

The historical data trend for TME Pharma NV's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

TME Pharma NV Total Operating Expense Chart

TME Pharma NV Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 13.45 12.00 5.62 5.26 2.86

TME Pharma NV Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2.87 2.74 2.52 1.96 0.90

TME Pharma NV Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €2.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €2.86 Mil mean?
TME Pharma NV (XPAR:ALTME) has a Total Operating Expense of €2.86 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on TME Pharma NV and its competitors.
Is TME Pharma NV's Total Operating Expense too high?
TME Pharma NV's current Total Operating Expense is €2.86 Mil.
How does TME Pharma NV's Total Operating Expense compare to VRTX and REGN?
TME Pharma NV's Total Operating Expense of €2.86 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Biotechnology company?
A good Total Operating Expense depends on the Biotechnology industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on TME Pharma NV and its competitors. TME Pharma NV's current Total Operating Expense is €2.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is TME Pharma NV stock overvalued right now?
TME Pharma NV (XPAR:ALTME) has a current Total Operating Expense of €2.86 Mil. The current Total Operating Expense is €2.86 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For TME Pharma NV (XPAR:ALTME), the current Total Operating Expense is €2.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

TME Pharma NV Business Description

Other Exchanges 0N6A:Germany
Address Max-Dohrn-Strasse 8-10, Berlin, DEU, 10589
TME Pharma NV is a clinical-stage biopharmaceutical company focused on developing novel therapies for treatment of the aggressive cancers and specializing in approaches targeting the tumor microenvironment. Its enhances the effectiveness of cancer treatments including current standards of care (such as antivascular agents, chemotherapy and radiotherapy) and immune-oncology approaches (such as immune checkpoint inhibitors). The company's Spiegelmer platform has generated a proprietary pipeline of clinical-stage product candidates including its cancer drug candidate NOX-A12 and its second clinical-stage asset, NOX-E36, now planned to be developed in eye diseases. The company has one segment active in pioneering the development of a new class of proprietary therapeutics called Spiegelmers.